Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Mirko Buchholz"'
Autor:
Kathrin Tan, Christian Jäger, Stefanie Geissler, Dagmar Schlenzig, Mirko Buchholz, Daniel Ramsbeck
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)
Targeting metalloproteinases has been in the focus of drug design for a long time. However, meprin α and β emerged as potential drug targets just recently and are linked to several diseases with different pathological background. Nevertheless, the
Externí odkaz:
https://doaj.org/article/6cf1ad89dd504526bad8c27cce359ded
Autor:
Leila Issmail, Christin Möser, Christian Jäger, Basma Altattan, Daniel Ramsbeck, Martin Kleinschmidt, Mirko Buchholz, David Smith, Thomas Grunwald
Publikováno v:
Frontiers in Virology, Vol 2 (2022)
Human respiratory syncytial virus (RSV) is the primary cause of acute lower respiratory tract infections in children and the elderly worldwide, for which neither a vaccine nor an effective therapy is approved. The entry of RSV into the host cell is m
Externí odkaz:
https://doaj.org/article/e691e42ef8224ec587f1da3b430fc2ac
Autor:
Daniel Ramsbeck, Nadine Taudte, Nadine Jänckel, Stefanie Strich, Jens-Ulrich Rahfeld, Mirko Buchholz
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1206 (2021)
Periodontitis is a severe yet underestimated oral disease. Since it is linked to several systemic diseases, such as diabetes, artheriosclerosis, and even Alzheimer’s disease, growing interest in treating periodontitis has emerged recently. The majo
Externí odkaz:
https://doaj.org/article/c83c92b5888541eb8c2136912ad25b5a
Autor:
Jan-Luca Schmid, Martin Kirchberg, Sandra Sarembe, Andreas Kiesow, Anton Sculean, Karsten Mäder, Mirko Buchholz, Sigrun Eick
Publikováno v:
Pharmaceutics, Vol 12, Iss 4, p 352 (2020)
Periodontal therapy using antimicrobials that are topically applied requires slow or controlled release devices. The in vitro antimicrobial activity of biodegradable polymer formulations that contain a new minocycline lipid complex (P-MLC) was evalua
Externí odkaz:
https://doaj.org/article/d7ff464fa7884dafb36d4e1676e75743
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 1, p 95 (2017)
Colicins are natural non-antibiotic bacterial proteins with a narrow spectrum but an extremely high antibacterial activity. These proteins are promising food additives for the control of major pathogenic Shiga toxin-producing E. coli serovars in meat
Externí odkaz:
https://doaj.org/article/ed5be1b760fe467b89a47991f4586d2c
Autor:
Stephanie Hielscher-Michael, Carola Griehl, Mirko Buchholz, Hans-Ulrich Demuth, Norbert Arnold, Ludger A. Wessjohann
Publikováno v:
Marine Drugs, Vol 14, Iss 11, p 203 (2016)
In recent years, many new enzymes, like glutaminyl cyclase (QC), could be associated with pathophysiological processes and represent targets for many diseases, so that enzyme-inhibiting properties of natural substances are becoming increasingly impor
Externí odkaz:
https://doaj.org/article/220f62f3723643dea6ecd9177e396cc2
Autor:
Kevin Böhm, Eric Schulze‐Niemand, Thilo Kähne, Elisa Siddiqui, Christian Täger, Daniel Ramsbeck, Mirko Buchholz, Michael Naumann
Publikováno v:
Archiv der Pharmazie.
Autor:
Franziska Seifert, Stephan Schilling, Oliver Kupski, Hans-Ulrich Demuth, Lisa-Marie Funk, Viktor Sautner, Franc Meyer, Ulf Diederichsen, Brigitte Worbs, Daniel Ramsbeck, Mirko Buchholz, Kai Tittmann
Publikováno v:
Biochemistry. 59:2585-2591
Amyloidogenic plaques are hallmarks of Alzheimer's disease (AD) and typically consist of high percentages of modified Aβ peptides bearing N-terminally cyclized glutamate residues. The human zinc(II) enzyme glutaminyl cyclase (QC) was shown in vivo t
Autor:
Miriam Linnert, Stephan Schilling, Hans-Ulrich Demuth, Mirko Buchholz, Jens-Ulrich Rahfeld, John A. Houston, Christoph Parthier, Florian Veillard, Nadine Taudte, Anke Piechotta, Milton T. Stubbs, Petr Kolenko, Jan Potempa, Daniel Ramsbeck, Sigrun Eick
Publikováno v:
The Journal of Biological Chemistry
Taudte, Nadine; Linnert, Miriam; Rahfeld, Jens-Ulrich; Piechotta, Anke; Ramsbeck, Daniel; Buchholz, Mirko; Kolenko, Petr; Parthier, Christoph; Houston, John A; Veillard, Florian; Eick, Sigrun; Potempa, Jan; Schilling, Stephan; Demuth, Hans-Ulrich; Stubbs, Milton T (2021). Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis. The journal of biological chemistry, 296, p. 100263. American Society for Biochemistry and Molecular Biology 10.1016/j.jbc.2021.100263
Taudte, Nadine; Linnert, Miriam; Rahfeld, Jens-Ulrich; Piechotta, Anke; Ramsbeck, Daniel; Buchholz, Mirko; Kolenko, Petr; Parthier, Christoph; Houston, John A; Veillard, Florian; Eick, Sigrun; Potempa, Jan; Schilling, Stephan; Demuth, Hans-Ulrich; Stubbs, Milton T (2021). Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis. The journal of biological chemistry, 296, p. 100263. American Society for Biochemistry and Molecular Biology 10.1016/j.jbc.2021.100263
The development of a targeted therapy would significantly improve the treatment of periodontitis and its associated diseases including Alzheimer's disease, rheumatoid arthritis, and cardiovascular diseases. Glutaminyl cyclases (QCs) from the oral pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b44849e5bf631c10995725a3bbf87c2
https://publica.fraunhofer.de/handle/publica/267517
https://publica.fraunhofer.de/handle/publica/267517
Autor:
Mirko Buchholz, Christian Jäger, Stefanie Geissler, Daniel Ramsbeck, Kathrin Tan, Dagmar Schlenzig, Walter Stöcker, Hagen Körschgen
Publikováno v:
Chemmedchem
Astacin metalloproteinases, in particular meprins α and β, as well as ovastacin, are emerging drug targets. Drug‐discovery efforts have led to the development of the first potent and selective inhibitors in the last few years. However, the most r